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We evaluated the eﬀects of moderate-to-severe impairment of the estimated glomerular ﬁltration rate (eGFR: 15 to 59mL/min
per 1.73m2) and of proteinuria on the central hemodynamics and the pulse wave velocity (PWV) in 2244 middle-aged healthy
Japanesemenwhowere notreceiving anymedicationsforcardiovasculardiseasesorcardiovascularriskfactors.Theadjusted value
ofthe radialaugmentationindex washigherin thesubjects with proteinuria than in thosewithoutproteinuria. On theother hand,
this value was similar between the subjects with and without moderate-to-severe impairment of the eGFR. Not only proteinuria
but alsomoderate-to-severe impairmentofthe eGFR wasassociatedwithincrease inthe adjusted valueofthe brachial-anklePWV.
Thus, proteinuria was found to be an independent risk factor for abnormal central hemodynamics and increased stiﬀness of the
large- to middle-sized arteries, while moderate-to-severe impairment of the eGFR was associated with an increase of the arterial
stiﬀness, but not with abnormalityof the central hemodynamics.
1.Introduction
Chronic kidney disease (CKD) is an independent risk factor
forcardiovasculardisease[1–3].Assessment oftheseverityof
CKD is employed in general health checkups for cardiovas-
cularriskstratiﬁcation[1–3].Estimatedglomerularﬁltration
rate (eGFR) (mL/min per 1.73m2) and presence/absence
of proteinuria are the key components measured during
assessment of the severity of CKD. A recent meta-analysis
demonstrated that the central hemodynamics (i.e., augmen-
tation index (AI) and central blood pressure (CBP)) and
pulse wave velocity (PWV), a marker of the stiﬀness of
large arteries, are independent risk factors for cardiovascular
disease and that these variables may reﬂect diﬀerent facets
of the pathophysiological abnormalities related to arterial
stiﬀness [4, 5]. Several studies have demonstrated abnormal
central hemodynamics and increased PWV in subjects with
end-stage renal disease (i.e., eGFR <15mL/min per 1.73m2)
[6, 7]. On the other hand, it has not yet been clearly revealed
whether moderate-to-severe impairment of the eGFR (15
to 59mL/min per 1.73m2)a n dp r o t e i n u r i am a ya l s ob e
associated with impairment of the central hemodynamics
and increase of the PWV [8, 9]. One of the reasons for
the inconclusiveness of this issue may be related to the
medications prescribed to the study subjects, because the
medications prescribed for the cardiovascular risk factors are
known to potentially aﬀect the central hemodynamics and
PWV [10].
Recently, we reported several ﬁndings of clinical studies
conducted by us on the arterial stiﬀness [11, 12]. Our study
subjects mostly comprised middle-aged healthy Japanese
men and revealed gender diﬀerences in the central hemo-
dynamic variables [13]. The present study was conducted
to evaluate the eﬀects of moderate-to-severe impairment of2 International Journal of Nephrology
the eGFR (15 to 59mL/min per 1.73m2)a n dp r o t e i n u r i ao n
the central hemodynamics and PWV in middle-aged healthy
Japanese men who were not receiving any medications for
cardiovascular disease or the cardiovascular risk factors.
2.Methods
2.1. Study Cohort. The study protocol has been described
in detail in a previous report [11, 12]. The study sub-
jects were all employees of a construction company who
underwent annual health checkup plus the measurements
of the brachial-ankle PWV and of the radial augmentation
index (radial AI) in 2008. The annual health checkup
was conducted in the morning hours after the subjects
had fasted overnight and included physical examinations,
blood pressure measurement (2 times), blood and urine
examinations, electrocardiography, chest roentgenography,
upper gastrointestinal roentgenography, audiometry, and
vision testing. In addition, measurements of the brachial-
ankle PWV and radial augmentation index (radial AI) were
also conducted during this series of examinations. The
following subjects were excludedfrom the study: (1) subjects
with conditions in which the reliability of the brachial-ankle
PWV measurement is considered to be questionable [11,
12] (atrial ﬁbrillation; ankle/brachial systolic blood pressure
index of less than 0.95; undergoing regular hemodialysis);
(2) subjects in whom the standard deviation of the radial AI,
calculated from ten radial pressure waveforms, was over 6%;
(3) subjects with serum C-reactive protein levels ≥10mg/L;
(4) subjects receiving medications for heart disease, stroke,
or risk factors for cardiovascular disease (i.e., hyperten-
sion, hypercholesterolemia, and/or diabetes mellitus). Verbal
informed consent was obtained from all of the participants
prior to the measurements. The study was conducted with
the approval of the Ethics Guidelines Committee of Tokyo
Medical University.
2.2. Measurements. Subjects were randomly allocated to
measurement of the brachial-ankle PWV ﬁrst, followed by
that of the radial AI, or to measurement of the radial AI ﬁrst,
followed by that of the brachial-ankle PWV. The procedural
details of both measurements are described elsewhere.
2.2.1. Augmentation Index. The measurements of the blood
pressure and radial AI were conducted after the subjects
had rested for 5 minutes in the sitting position, in an air-
conditioned room (24–26◦C) earmarked exclusively for this
purpose. The blood pressure was measured in the right
upper arm by the oscillometric method (HEM-907; Omron
Healthcare Co., Ltd., Kyoto, Japan). Immediately after this
measurement, the left radial arterial waveform was recorded
using an arterial applanation tonometry probe equipped
with an array of 40 micropiezoresistive transducers (HEM-
9000AI; Omron Healthcare Co., Ltd. Kyoto, Japan) [12, 13].
The HEM-9000AI device is programmed to automatically
determine the pressure against the radial artery to yield
the optimal radial arterial waveforms, and 10 radial arterial
pressure waveforms were recorded. Then, the ﬁrst and
second peaks of the peripheral systolic pressure (SBP1 and
SBP2)andradialdiastolicpressure(DBP)wereautomatically
detected, and the radial AI was calculated using the equation
(SBP2−DBP)/(SBP1−DBP) ×100(%).Thewaveformdata
were conﬁrmed by well-trained technicians, and the data of
subjectswith astandard deviationofthe radial AIofover6%
were excluded from the analysis. The radial AI values were
adjusted to a heart rate of 75 beats/minute (radial AI75).
2.3. Pulse Wave Velocity. T h eb r a c h i a l - a n k l eP W Vw a s
measured using a volume-plethysmographic apparatus
(Form/ABI, OMRON Colin Co. Ltd., Kyoto, Japan) [11, 12].
In brief, electrocardiographic electrodes were placed on both
wrists, anda microphonefor thephonocardiogram was ﬁxed
to the left chest. Occlusion cuﬀs, which were connected to
both the plethysmographic and oscillometric sensors, were
tied around both upper arms and both ankles, with the
subjects lying supine. The brachial and posttibial arterial
pressures were measured using the oscillometric sensor.
The brachial and posttibial arterial pressure waveforms
determinedbytheplethysmographicsensorandrecordedfor
10seconds were stored. The measurements were conducted
after the subjects had rested for at least 5 minutes in
the supine position in an air-conditioned room (24–26◦C)
designated exclusively for this purpose.
2.4. Laboratory Measurements. The serum levels of total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL), and triglycerides (TG) and the fasting plasma
glucose (FPG) were measured enzymatically (FALCO
Biosystems Co. Ltd, Tokyo, Japan). The serum CRP level was
determined by the latex-aggregation method (Eiken Co.,
Tokyo, Japan), which is a high-sensitivity assay method with
a detection threshold of <0.1mg/L. All the blood and urine
samples were obtained in the morning after the patients had
fasted overnight.
The severity of the renal function impairment was
determined based on measurement of the eGFRcr using the
Modiﬁcation of Diet in Renal Disease (MDRD) equation for
Japanese subjects [3]: eGFRcr = 194 × Crnn−1.094× Age−0.287
(in females, ×0.739).
A urinary dipstick test result for proteinuria of >1+
(urinary protein concentration ≥30mg/dl) was deﬁned as
proteinuria [2, 3, 12].
2.5.Statistical Analysis. Thedatawererepresentedasmean ±
SD. The basic covariates used for the adjustments were
the age, height, waist circumference, smoking status (non-
or past smoker: 0, present smoker: 1), alcohol intake
status (nondrinker: 0, light-to-moderate drinker (ethanol
consumption, 1–29g/day): 1, and heavy drinker (ethanol
consumption, over 30g/day): 2) TC, HDL, TG, and FPG.
For assessment of the diﬀerences in each variable among
the groups, an unpaired t-test for continuous variables
and the chi-squared test for categorical variables were
applied.Furthermore,forassessment ofthediﬀerencesinthe
brachial-ankle PWV, radial AI, and SBP2 among the groups,
a general linear model (GLM) analysis with adjustments wasInternational Journal of Nephrology 3
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Figure 1: Adjusted values of the radial augmentation index, second
peak of the radial pressure waveform, and brachial-ankle pulse
wave velocity in subjects classiﬁed by the presence/absence of
proteinuria or eGFR ≥ 60mL/min per 1.73m2/<60mL/min per
1.73m2. Abbreviations. radial AI: radial augmentation index; SBP2:
second peak of the radial pressure waveform; baPWV: brachial-
ankle pulse wave velocity; ∗P<. 05 versus subjects without
proteinuria; †P<. 05 versus subjects with eGFR ≥ 60mL/min per
1.73m2.
applied. All the analyses were conducted using the SPSS
software for Windows, version 11.0J (SPSS, Chicago, Ill,
USA); P values < .05 were considered to denote statistical
signiﬁcance.
3.Results
Initially, 2740 male subjects were enrolled in the present
study. However, 496 subjects were excluded because they had
atrial ﬁbrillation (n = 13), had an ABI of less than 0.95
Table 1: Clinical characteristics of the entire study population.
Parameter
number 2244
Age (y) 44 ±9
Height (cm) 172 ± 6
BMI 23.9 ±3.0
WC (cm) 84 ±8
Smoking(%) 707 (32)
ALC (N/LM/H) (%) 291/1386/567 (13/62/25)
SBP (mmHg) 123 ±13
DBP (mmHg) 76 ±11
Pulse rate (bpm) 68 ±10
baPWV (m/s) 12.9 ±1.8
radial AI (%) 71 ±13
SBP 2 (mmHg) 111 ±16
TC (mmol/L) 5.4 ±0.9
HDL (mmol/L ) 1.6 ±0.4
TG (mmol/L) 1.4 ±1.0
FPG (mmol/Ll) 4.9 ±0.6
eGFR (mL/min per 1.73m2)8 2 ±12
eGFR <60 mL/min per 1.73m2 (%) 48 (2.1)
Proteinuria (%) 65 (2.9)
Abbreviations. BMI: body mass index; WC: waist circumference; smoking:
number of subjects who were smoking; ALC: (N: nondrinker, LM: light-
to-moderate drinker (ethanol intake: 1–29g/day), and H: heavy drinker
(ethanol intake: ≥30g/day)); SBP: systolic blood pressure; DBP: diastolic
blood pressure; baPWV: brachial-anklepulse wave velocity;radial AI: radial
augmentation index; SBP2: second peak of the radial pressure waveform;
TC: serum total cholesterol; HDL: serum high-density lipoprotein choles-
terol; TG:serum triglycerides;FPG: fastingplasmaglucose;eGFR:estimated
glomerular ﬁltration rate; eGFR < 60mL/min per 1.73m2:n u m b e ro f
subjects with eGFR < 60mL/min per 1.73m2; proteinuria: number of
subjects with proteinuria.
(n = 14),were undergoingregular hemodialysis (n = 2),had
a standard deviation of the radial AI of over 6% (n = 68),
had a serum CRP level >10mg/L (n = 31), were receiving
medications for heart disease (n = 26), stroke (n = 12),
or risk factors for cardiovascular disease (i.e., hypertension
(n = 250), hypercholesterolemia (n = 46), and/or diabetes
mellitus (n = 44)). Finally, the data of 2244 subjects were
included for the analysis in this study.
Table 1 shows the clinical characteristics of the entire
study population. In the entire study population, 48 subjects
h a da ne G F Ro f1 5t o5 9 m L / m i np e r1 . 7 3 m 2,a n d6 5
subjects had proteinuria. Table 2 summarizes the clinical
characteristics in the subjects with eGFR ≥ 60mL/min per
1.73m2/eGFR = 15 to 59mL/min per 1.73m2 with/without
proteinuria. The body mass index, brachial-ankle PWV,
SBP2, TC, TG, and FBG were higher, and the percentage
of current smokers and blood pressure were lower in the
subjects with an eGFR = 15 to 59mL/min per 1.73m2 than
in those with an eGFR ≥ 60mL/min per 1.73m2.A g e ,b o d y
mass index, percentage of current smokers, blood pressure,
brachial-ankle PWV, radial AI,and SBP2were higher andthe
serum HDL was lower in the subjects with proteinuria than
in those without proteinuria.4 International Journal of Nephrology
Table 2: Clinical characteristics of the study subjects classiﬁed by the presence/absence of proteinuria.
Pro (+) Pro (−) P-value eGFR < 60 eGFR ≥ 60 P value
Number 65 2179 48 2196
Age (y) 43 ±10 44 ±9 .69 54 ±84 4 ±9 <.01
Height (cm) 172 ±6 172 ±6 .21 172 ±6 172 ±6. 9 2
BMI 25.1 ±4.12 3 .9 ±3.0 <.05 24.6 ±2.62 3 .9 ±3.0 <.05
WC (cm) 87 ±11 84 ±8 <.05 86 ±68 4 ±8. 0 9
Smoking(%) 30 (46) 677 (31) <.01 7 (15) 700 (32) <.01
ALC (N/LM/H)(%) 12/34/19 (18/52/30) 279/1352/548 (13/62/25) .25 5/32/11 (10/67/23) 286/1354/556 (13/62/25) .76
SBP (mmHg) 126 ±15 122 ±14 <.05 130 ±15 122 ±14 <.01
DBP (mmHg) 79 ±12 76 ±11 <.05 84 ±12 76 ±11 <.01
Pulse rate (bpm) 71 ±96 8 ±10 <.05 71 ±96 8 ±10 .07
baPWV (m/s) 13.7 ±2.11 2 .9 ±1.8 <.01 14.5 ±2.31 2 .9 ±1.8 <.01
radial AI (%) 74 ±10 71 ±13 <.05 73 ±14 71 ±13 .12
SBP 2 (mmHg) 117 ±17 111 ±16 <.01 120 ±19 111 ±16 <.01
TC (mmol/L) 5.5 ±1.05 .3 ±0.9. 1 9 5 .9 ±1.05 .3 ±0.9 <.01
HDL (mmol/L ) 1.4 ±0.41 .6 ±0.4 <.01 1.5 ±0.41 .6 ±0.4. 1 6
TG (mmol/L) 1.6 ±1.71 .4 ±1.0. 3 1 1 .8 ±1.01 .4 ±1.0 <.01
FPG (mmol/Ll) 5.2 ±0.54 .9 ±0.5. 1 2 5 .1 ±0.54 .9 ±0.5 <.01
eGFR (mL/min per 1.73m2)8 5 ±15 82 ±12 .10 56 ±48 2 ±12 <.01
eGFR < 60 (%) 1 (1.5) 64 (2.9) .59 — — —
Proteinuria (%) — — — 1 (2.0) 47 (2.1) .75
Abbreviations. Pro (+): subjects with proteinuria; Pro (−): subjects without proteinuria; eGFR < 60: subjects with eGFR of 15 to 59mL/min per 1.73m2;
eGFR ≥ 60: subjectswitheGFR ≥ 60mL/min per 1.73m2; BMI: body massindex;WC: waistcircumference;smoking: number of subjectswho were smoking;
ALC: (N: nondrinker, LM: light-to-moderate drinker (ethanol intake: 1–29g/day), and H: heavy drinker (ethanol intake: ≥30g/day)); SBP: systolic blood
pressure; DBP: diastolic blood pressure; baPWV: brachial-ankle pulse wave velocity; radial AI: radial augmentation index; SBP2: second peak of the radial
pressure waveform; TC: serum total cholesterol; HDL: serum high-density lipoprotein cholesterol; TG: serum triglycerides; FPG: fasting plasma glucose;
eGFR: estimatedglomerular ﬁltration rate; eGFR < 60mL/min per 1.73m2: number of subjectswith eGFR < 60mL/min per 1.73m2; proteinuria: number of
subjects with proteinuria.
A f t e rt h ea d j u s t m e n t s( b a s i cc o v a r i a t e sp l u se G F R ,m e a n
blood pressure, and pulse rate obtained at the time of
measurement of the radial AI), the value of the radial AI
was higher in the subjects with proteinuria than in those
without proteinuria (Figure 1(a)). However, the adjusted
(basic covariates plus presence/absence proteinuria, mean
blood pressure, and pulse rate obtained at the time of
measurement of the radial AI) value was similar between the
subjects with an eGFR of 15 to 59mL/min per 1.73m2 and
those with an eGFR ≥60mL/min per 1.73m2.F u r t h e r m o r e ,
the adjusted (basic covariatesp l u se G F R ,p u l s er a t eo b t a i n e d
at the measurement of radial AI) value of SBP2 was
also higher in the subjects with proteinuria than in those
without proteinuria (Figure 1(b)). On the other hand, after
the adjustments (basic covariates plus eGFR, mean blood
pressure, and pulserate obtained at thetime of measurement
of brachial-ankle PWV), the value of the brachial-ankle
PWV was higher in the subjects with proteinuria than in
those without proteinuria. The adjusted (basic covariates
plus presence/absence proteinuria, mean blood pressure,
and pulse rate obtained at the measurement of brachial-
ankle PWV) value of the brachial-ankle PWV was also
higher in the subjects with eGFR of 15 to 59mL/min per
1.73m2 than in those with eGFR ≥ 60mL/min per 1.73m2
(Figure 1(c)).
4.Discussion
The present study was conducted to examine the eﬀect of
proteinuria and that of moderate-to-severe impairment of
the eGFR (15 to 59mL/min per 1.73m2)o nt h ec e n t r a l
hemodynamics and PWV in healthys u b j e c t s( i . e . ,t h o s ew h o
were not receiving any medication for cardiovascular disease
or cardiovascular risk factors).
Central hemodynamics and PWV are markers reﬂect-
ing the pathophysiological abnormalities related to arterial
stiﬀness [4, 5, 14]. Vascular damage of the systemic arte-
rial tree aﬀects the central hemodynamics, while vascular
damage of the large- to middle-sized arteries are major
determinants of the brachial-ankle PWV [4, 5, 14]. Few
studieshavesimultaneously examined theeﬀectsofimpaired
GFR and proteinuria on the central hemodynamics and
arterial stiﬀness, especially central arterial stiﬀness [8, 9].
The Framingham study demonstrated that the presence of
microalbuminuria, but not the eGFR, was related to an
increased AI and increased carotid-femoral PWV, the golden
standard as a marker of the central arterial stiﬀness [8].
The Hoon study demonstrated that while microalbuminuria
was related to increased AI and increased carotid arterial
stiﬀness, impaired eGFR was related to only increased
carotid arterial stiﬀness [9]. However, in both studies,International Journal of Nephrology 5
around 30–40% of the subjects were receiving medication
for hypertension [8, 9], which potentially aﬀects the AI
and PWV [10]. Thus, the present study was conducted
in subjects who were not receiving any medications for
either cardiovascular disease or for risk factors and demon-
strated that proteinuria was associated with an increased
brachial-ankle PWV, radial AI, and SBP2, whereas impaired
eGFR was associated with only increase of the brachial-
ankle PWV. Therefore, proteinuria may be associated with
vascular damage of the central and peripheral arteries, and
impaired GFR may be associated with vascular damage
only of the large- to middle-sized arteries in healthy
subjects.
Recent prospective studies have demonstrated that in-
creased stiﬀness of the larger arteries, as assessed by the
carotid-femoral PWV, or of the large- to middle-sized
arteries,asassessed bythebrachial-anklePWV,isariskfactor
for the progressive decline of the GFR or the new onset
of microalbuminuria [8, 15–17]. On the other hand, only
the Framingham study has been conducted to evaluate the
clinical signiﬁcance of abnormal central hemodynamics in
predicting the future incidence of CKD or microalbumin-
uria;however,noclinicalsigniﬁcance ofthesevariablescould
be found in this study [8]. However, kidney has luxury blood
ﬂow because of the low resistance to blood ﬂow, therefore,
small arterial vessels in the kidney are exposed to high-
pressure ﬂuctuations,especially in cases with elevatedcentral
blood pressure [18]. Thus, a further prospective study is
proposed to examine whether abnormal central hemody-
namicsmight be apredictoroftheprogression ofglomerular
damage, new onset of proteinuria, and/or the aggravation of
proteinuria.
The present study had some limitations. First, persistent
proteinuria is one of the criteria for the diagnosis of
CKD, but in the present study, only the results of spot
proteinuria asassessed bytheurinary dipstick testwere avail-
able. Second, while the urinary microalbumin-to-creatinine
excretion ratio is another recommended parameter for
estimating the severity of renal dysfunction [8, 16], we did
not measure this parameter. Third, brachial-ankle PWV is
primarily a marker of stiﬀness of the aorta and middle-
sized arteries and closely associated with not only the aortic
PWV, as assessed by a direct catheter method, but also
with the carotid-femoral PWV [11, 19], the most well-
established index for the measurement of aortic stiﬀness
[4, 5, 8].
5.Conclusion
In middle-aged healthy Japanese subjects, who were not
receivingmedicationsforcardiovasculardiseases ortheirrisk
factors, proteinuria was found to be an independent risk
factor for abnormal central hemodynamics and increased
stiﬀness of the large- to middle-sized arteries. On the other
hand, moderate-to-severe impairment of the eGFR (15 to
59mL/min per 1.73m2) was only associated with increased
arterial stiﬀness.
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